Literature DB >> 9300743

Serum testosterone levels after external beam radiation for clinically localized prostate cancer.

G K Zagars1, A Pollack.   

Abstract

PURPOSE: To determine whether serum total testosterone levels change after external beam radiation therapy for localized prostate cancer. METHODS AND MATERIALS: Eighty-five men with clinically localized prostate cancer (T1-T3, N0/NX, M0) who underwent external beam radiation therapy without androgen ablation had pretreatment and 3-month posttreatment total serum testosterone levels determined by radioimmunoassay. Scattered doses to the testicles were measured with thermoluminescent dosimetry in 10 men.
RESULTS: Pretreatment serum testosterone levels ranged from 185 to 783 ng/dl, with a mean of 400 ng/dl and a median of 390 ng/dl. The coefficient of variation was 30%. Postradiation 3-month testosterone levels ranged from 163 ng/dl to 796 ng/dl, with mean and median values of 356 ng/dl and 327 ng/ml, respectively. The coefficient of variation was 34%. The 3-month value was significantly lower than the pretreatment value (Wilcoxon paired p = 0.0001). The mean absolute fall was 94 ng/dl and the mean percentage fall was 9%. Although the fall in testosterone level was statistically significant, the difference was very small quantitatively. In contrast, serum prostate-specific antigen levels fell dramatically by 3 months after radiation. Testicular scattered doses ranged from 1.84 to 2.42 Gy, with a mean of 2.07 Gy for a prostatic tumor dose of 68 Gy.
CONCLUSIONS: Although significant, the fall in serum testosterone level after radiation for localized prostate cancer was small and likely of no pathophysiologic consequence. It is unlikely that scattered testicular radiation plays any significant role in the genesis of this change in testosterone level, which most likely occurs as a nonspecific stress response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9300743     DOI: 10.1016/s0360-3016(97)00311-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

Review 1.  Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities).

Authors:  Marigdalia K Ramirez-Fort; Marc J Rogers; Roberto Santiago; Sean S Mahase; Melissa Mendez; Yi Zheng; Xiang Kong; James A Kashanian; M Junaid Niaz; Shearwood McClelland; Xiaodong Wu; Neil H Bander; Peter Schlegel; John P Mulhall; Christopher S Lange
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-19

Review 2.  Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?

Authors:  Phillip J Gray; Jason A Efstathiou
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

3.  Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy.

Authors:  Hideyasu Tsumura; Takefumi Satoh; Hiromichi Ishiyama; Shuhei Hirano; Ken-Ichi Tabata; Shinji Kurosaka; Kazumasa Matsumoto; Tetsuo Fujita; Masashi Kitano; Shiro Baba; Kazushige Hayakawa; Masatsugu Iwamura
Journal:  World J Radiol       Date:  2015-12-28

4.  Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists.

Authors:  Howard Huaihan Pai; Tom Pickles; Mira Keyes; Stuart Jones; Rachel E McDonald; Mary Lesperance; Eric Berthelet
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862

5.  Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy.

Authors:  S Slater; R T Oliver
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

Review 6.  Secondary Cancers After Radiation Therapy for Primary Prostate or Rectal Cancer.

Authors:  Yen-Chien Lee; Chung-Cheng Hsieh; Chung-Yi Li; Jen-Pin Chuang; Jenq-Chang Lee
Journal:  World J Surg       Date:  2016-04       Impact factor: 3.352

7.  Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer.

Authors:  Jeffrey M Martin; Elizabeth A Handorf; Robert A Price; George Cherian; Mark K Buyyounouski; David Y Chen; Alexander Kutikov; Matthew E Johnson; Chung-Ming Charlie Ma; Eric M Horwitz
Journal:  Med Dosim       Date:  2015-01-13       Impact factor: 1.482

8.  Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.

Authors:  Bo Dai; Yuan-Yuan Qu; Yun-Yi Kong; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Wei-Yi Yang
Journal:  Asian J Androl       Date:  2013-05-27       Impact factor: 3.285

9.  Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.

Authors:  James L Gulley; Jeanny B Aragon-Ching; Seth M Steinberg; Maha H Hussain; Oliver Sartor; Celestia S Higano; Daniel P Petrylak; Gurkamal S Chatta; Philip M Arlen; William D Figg; William L Dahut
Journal:  J Urol       Date:  2008-08-16       Impact factor: 7.450

10.  131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

Authors:  Naoya Hattori; Ajay K Gopal; Andrew T Shields; Darrell R Fisher; Ted Gooley; John M Pagel; Oliver W Press; Joseph G Rajendran
Journal:  Nucl Med Commun       Date:  2012-12       Impact factor: 1.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.